The complaint alleges that Zoetis violated the Securities Exchange Act of 1934 by issuing misleading statements to the market. According to the lawsuit, the company failed to disclose that its Librela medication experienced stunted prescription growth following FDA safety warnings regarding neurological complications in dogs. Furthermore, the filing claims the company lost significant market share across its primary product lines, including its Trio heartworm preventative and dermatology staples Apoquel and Cytopoint, as new competitors entered the space.
Zoetis Faces Class Action Lawsuit Over Alleged Misleading Statements
Investors who purchased Zoetis Inc. securities between January 14, 2025, and May 6, 2026, are being urged to join a class action lawsuit filed by The Schall Law Firm. The litigation centers on allegations that the pharmaceutical company provided false information regarding its veterinary medication performance.
Shareholders who incurred losses during this period have until July 27, 2026, to contact The Schall Law Firm to participate in the pending litigation. While the class has not yet been certified, investors are currently considered absent class members. Those interested in discussing their legal rights or potential recovery can reach Brian Schall at the firm's Los Angeles office or via their official website.
Comments (0)
No comments yet. Be the first!